Study summary
Adding low-dose whole-brain radiation lengthened remission without harming thinking
78.7%2-year progression-free with low-dose radiation, vs 54%
What was tested
R-MPV-A chemoimmunotherapy with or without reduced-dose whole-brain radiotherapy (23.4 Gy) in newly diagnosed PCNSL.
What they found
- 2-year progression-free survival was 78.7% with low-dose radiation vs 54% without (hazard ratio 0.47).
- Overall survival did not differ significantly.
- Thinking and memory tests showed no harm from the low-dose radiation.
What it means
An alternative to transplant for patients who cannot have high-dose chemotherapy.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.